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Laboratory Studies
Vasodepressor Role of Endogenous Bradykinin
Assessed by a Bradykinin Antagonist
ATHANASSIOS BENETOS, HARALAMBOS GAVRAS, JOHN M. STEWART, RAYMOND J. VAVREK, SIMON HATINOGLOU, AND IRENE GAVRAS
SUMMARY This study was designed to examine the contribution of bradykinin to the depressor effect of different antihypertensive drugs in two-kidney renovascular hypertensive rats, using a new specific antagonist of bradykinin. First, the inhibitory capacity of this peptide for exogenously injected bradykinin (75-200 ng) was tested. An inhibition of the vasodepressor action of bradykinin by over 50% was found when the bradykinin inhibitor was infused at a rate of 40 /xg/min, with little difference at higher rates of infusion. This inhibitor then was infused in three groups of renovascular hypertensive rats after their blood pressure had been decreased by pretreatment with the converting enzyme inhibitor enalapril (MK 421), saralasin, or sodium nitroprusside, respectively. Infusion of the inhibitor produced an immediate 30% increase in blood pressure only in the enalapril-treated group. These results indicate that bradykinin is involved in the decrease of blood pressure produced by converting enzyme inhibition in experimental renovascular hypertension. (Hypertension 8: 000-000, 1986) KEY WORDS • experimental renovascular hypertension • converting enzyme inhibitor saralasin • sodium nitroprusside A LTHOUGH bradykinin (BK) is considered to be / \ a powerful vasodilator, 1 its contribution to A. \ -blood pressure regulation remains obscure. Exogenous BK injected systemically causes a decrease in blood pressure, 2 but it is rapidly inactivated after passage through the pulmonary vascular bed. 3 Following the discovery of a BK-potentiating factor by Ferreira, 4 it was demonstrated that the kininase II degrading BK in the lung and the angiotensin converting enzyme (ACE) transforming the inactive angiotensin I into the biologically active angiotensin II are in fact identical 5 and that both effects are inhibited by the same factor. 6 Theoretically, both actions should contribute to the hypotensive effect of various ACE inhibitors, yet only the elimination of angiotensin II has been proved beyond doubt. The actual accumulation of BK remains controversial, 7 " 9 and its role is mostly based on indirect evidence. 10 " 12 In several instances, the action of a vasoactive hormone has been demonstrated by the use of a specific competitive antagonist of that hormone at the vascular receptor level; examples include saralasin to determine the pressor effect of angiotensin II 13 and V, antagonists to prove the pressor effect of vasopressin.
14 In this study, we used a competitive antagonist of BK, the compound B4146 (synthesized by J.M.S. and R.J.V.), to prove that the depressor effect of ACE inhibition is indeed partly due to BK. The inhibitory capacity of this agent has been demonstrated in vitro on vascular, uterine, and ileum smooth muscle. 13 -16 Materials and Methods The first part of the study consisted of a series of experiments designed to test the inhibitory capacity of the BK inhibitor B4146 (Arg-Pro-Hyp-Gly-Thi-SerDPhe-Thi-Arg.TFA; Hyp = L^-hydroxyproline; Thi = /3-(2-thienyl)-L-alanine; TFA = trifluoracetic acid). To this aim, nine male Wistar rats (Charles River Breeding Laboratories, Wilmington, MA, USA) weighing 250 to 350 g at the time of the study were used. One day before the experiment, the right external iliac artery and the right femoral vein were cannulated with PE-50 catheters for direct arterial pressure recording and drug infusions, respectively. On the day of the experiment, the unanesthetized, unrestrained rats were pretreated with the converting enzyme inhibitor enala- VOL 8, No 11, NOVEMBER 1986 pril (MK-421), 1 mg/kg i.v. Thirty to 60 minutes later, when a stable blood pressure was obtained, a series of intra-arterial injections of BK was given over a period of 20 minutes while blood pressure was continuously recorded on a Hewlett-Packard recorder (Model 77028; Lexington, MA, USA). Three different doses (75, 120, and 200 ng) were used, and each was given in triplicate at 5-minute intervals. The volume of each injection was 0.2 ml. The same procedure was repeated during a continuous infusion of the BK inhibitor (40 pig/min i.v. over 20 minutes). Thirty minutes after the end of the BK inhibitor infusion, the same series of BK injections were repeated for a total of 27 injections in each rat. The dose of 40 /xg/min was chosen after pilot experiments showed that a dose of 20 /xg/min produced inhibition consistently lower than 50% whereas a dose of 80 /ig/min produced results essentially similar to those of the 40 /ig/min dose in the same rats.
In the second part of the experiment, renovascular hypertensive Wistar rats (two-kidney, one clip) weighing 250 to 350 g were used. One day before the experiment, all rats were cannulated with three PE-50 catheters (iliac artery, femoral, and jugular veins). On the day of the experiment, the rats were maintained unanesthetized and unrestrained in a glass cage. Blood pressure was recorded for 30 to 60 minutes, and only rats showing a mean arterial pressure of greater than 150 mm Hg were included in the protocol.
All drugs used in this study were dissolved in 5% dextrose. They included enalapril (Merck Sharp & Dohme, West Point, PA, USA), 1 mg/ml; saralasin (Eaton Laboratories, Norwich, NY, USA), 200 Mg/ml; sodium nitroprusside, 600 /xg/ml; and B4146, the BK inhibitor, 200 /i.g/ml. This peptide was synthesized in a manner analogous to that described for other BK antagonists. 16 Group 1 rats (n = 19) were pretreated with enalapril, 1 mg/kg i.v. A stable blood pressure was obtained after 30 to 90 minutes. At that time, 13 rats received a continuous intravenous infusion of BK inhibitor (40 Mg/min) over a period of 10 minutes and six received the same volume (0.2 ml/min) of 5% dextrose.
In Group 2 (ji = 13), saralasin, 10 /ig/kg/min i.v., was continuously infused. Twenty to 30 minutes after initiation of the infusion, when a stable blood pressure was obtained, the continuous infusion of BK inhibitor (n = 10) or 5% dextrose (n = 3) was started as in Group 1. Saralasin was infused continuously throughout the infusion of BK inhibitor or dextrose and for 30 minutes after the end of the latter infusion. The next day, seven of these rats received the same treatment as in Group 1 (enalapril followed by BK inhibitor).
Group 3 rats (n = 9) were pretreated with sodium nitroprusside (10 /ng/min i.v., continuous infusion) to obtain the same decrease in blood pressure as in Group 1. After blood pressure stabilized, infusion of the BK inhibitor (n = 6) or 5% dextrose (n = 3) was started as in the other groups.
Animal handling and experimental procedures followed were in accordance with institutional regulations.
All results were expressed as means ± SEM. Statistical comparisons were made by one-way analysis of variance followed whenever F was significant by unpaired or paired t test with the Bonferroni correction. Correlations were calculated by linear regression analysis. A p value of less than 0.05 was considered significant. Table 1 shows the inhibitory effect of the BK inhibitor B4146, 40 /ig/min, on the depressor effect of BK. The average degree of inhibition was over 50%. The specificity of BK inhibition by this compound was demonstrated by the lack of prevention of hypotension induced by other vasodilators (e.g., sodium nitroprusside). Figure 1 summarizes the results of the second part of the study. Although baseline blood pressures tended to be somewhat lower in Group 1 rats, they were not significantly different from those in the other two groups. In Group 1, blood pressure fell by 41 ± 5 mm Hg after enalapril administration (from 168 ± 6 to 127 ± 5 mm Hg;p <0.001). Infusion of the BK inhibitor caused an immediate 8 mm Hg increase in blood pressure in seven out of the 13 rats (mean, 12 ± 3 mm Hg), whereas no change in blood pressure was observed in the six remaining rats. For the group as a whole, this change after the BK inhibitor was statistically significant (p<0.01). No correlation was found between the vasopressor effect of the BK inhibitor and the baseline blood pressure level or the decrease of the arterial pressure in response to enalapril.
Results
In Group 2, the blood pressure decreased by 25 ± 6 mm Hg after the saralasin infusion (from 181 ± 6 to 156 ± 7 mm Hg; p<0.001). This fall tended to be smaller than that produced by enalapril in Group 1, but the difference did not attain statistical significance. Infusion of the BK inhibitor caused no change in the arterial pressure. Seven of these rats were used again the next day, but this time received the same treatment as in Group 1. Administration of enalapril caused a fall in blood pressure similar to that observed in the first group (from 179 ± 8 to 139 ± 6 mm Hg; p<0.001). Blood pressure increased in five out of seven of these animals after the infusion of the BK inhibitor. The Values are means ± SEM of 27 studies (i.e., rats injected in triplicate).
*p < 0.001, compared with values with no B4146 administered.
